974 related articles for article (PubMed ID: 30566941)
21. An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
Brown L; Skopit S
J Drugs Dermatol; 2018 Aug; 17(8):914-917. PubMed ID: 30124734
[TBL] [Abstract][Full Text] [Related]
22. Role of janus kinase inhibitors in the treatment of alopecia areata.
Triyangkulsri K; Suchonwanit P
Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
[TBL] [Abstract][Full Text] [Related]
23. Janus kinase inhibitors for alopecia areata.
King BA; Craiglow BG
J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
[TBL] [Abstract][Full Text] [Related]
24. Real-world experience and long-term evaluation of tofacitinib in refractory alopecia areata: A prospective, open-label, single-center study in Asian Arab population.
Husein-ElAhmed H; Abdulla N; Al-Obaidli A; Ali-Alam M; Steinhoff M
Dermatol Ther; 2022 Dec; 35(12):e15871. PubMed ID: 36177791
[TBL] [Abstract][Full Text] [Related]
25. A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata.
Deeb M; Beach RA
J Cutan Med Surg; 2017; 21(6):562-563. PubMed ID: 28635319
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of systemic minoxidil and tofacitinib combination in treatment-resistant alopecia universalis.
Dincer D; Tanacan E; Kose Ozkan C
J Cosmet Dermatol; 2021 Jun; 20(6):1807-1809. PubMed ID: 33098729
[TBL] [Abstract][Full Text] [Related]
27. Oral tofacitinib for the treatment of alopecia areata in pediatric patients.
Kibbie J; Kines K; Norris D; Dunnick CA
Pediatr Dermatol; 2022 Jan; 39(1):31-34. PubMed ID: 34779041
[TBL] [Abstract][Full Text] [Related]
28. Ruxolitinib for the treatment of severe alopecia areata.
Liu LY; King BA
J Am Acad Dermatol; 2019 Feb; 80(2):566-568. PubMed ID: 30195572
[No Abstract] [Full Text] [Related]
29. Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib.
Fetter T; Rios GC; Niebel D; Bieber T; Wenzel J
Acta Derm Venereol; 2020 May; 100(10):adv00144. PubMed ID: 32285135
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study.
Shin JW; Huh CH; Kim MW; Lee JS; Kwon O; Cho S; Park HS
Acta Derm Venereol; 2019 Jan; 99(1):41-46. PubMed ID: 30281139
[TBL] [Abstract][Full Text] [Related]
31. Tofacitinib as a treatment of alopecia areata in adolescents.
Morales-Miranda AY; Bueno-Arias GM; Aguirre-Félix ÓG; Tovar-Franco R
Bol Med Hosp Infant Mex; 2019; 76(4):182-187. PubMed ID: 31303654
[TBL] [Abstract][Full Text] [Related]
32. [Alopecia areata with good response to tofacitinib].
Maksimow A; Stintzing D; Wohlrab J
Hautarzt; 2021 Jun; 72(6):525-527. PubMed ID: 33044559
[TBL] [Abstract][Full Text] [Related]
33. Janus kinase inhibitors for alopecia areata: A narrative review.
Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
[TBL] [Abstract][Full Text] [Related]
34. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
[TBL] [Abstract][Full Text] [Related]
35. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
[TBL] [Abstract][Full Text] [Related]
37. What's New in Hair Loss.
Santos LDN; Shapiro J
Dermatol Clin; 2019 Apr; 37(2):137-141. PubMed ID: 30850035
[TBL] [Abstract][Full Text] [Related]
38. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.
King B; Lee AI; Choi J
J Invest Dermatol; 2017 Apr; 137(4):951-954. PubMed ID: 27887955
[No Abstract] [Full Text] [Related]
39. Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
Salman A; Sarac G; Ergun T
Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469706
[TBL] [Abstract][Full Text] [Related]
40. Tofacitinib for the treatment of lichen planopilaris: A case series.
Yang CC; Khanna T; Sallee B; Christiano AM; Bordone LA
Dermatol Ther; 2018 Nov; 31(6):e12656. PubMed ID: 30264512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
